IV treatment for a rare type of brain bleed
Raised to date
$15M
of $30M offered across 1 Form D filing
Grace Therapeutics, Inc. is a late-stage biopharmaceutical company dedicated to the development of innovative drug delivery technologies aimed at improving treatments for rare and orphan diseases. With a focus on enhancing the performance of existing therapies, the company seeks to expedite the onset of action, augment efficacy, minimize side effects, and provide more user-friendly delivery options for patients.
Grace Therapeutics stands out through its commitment to addressing rare diseases with novel delivery methods that promise significant improvements in patient outcomes.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Feb 25, 2025 | Equity | $15M/ $30M | Form D |
IV Drug Therapy
GTx-104 is an intravenous infusion specifically designed for treating aneurysmal subarachnoid hemorrhage (aSAH), a rare and life-threatening condition characterized by bleeding on the surface of the brain. This product is currently in late-stage clinical development.
Built for
Patients with rare and orphan diseases
